Glenmark Pharmaceuticals has received a Form 483 with six observations following a US FDA Good Manufacturing Practices (GMP) inspection of its manufacturing facility in Goa. According to reports from CNBC TV18, the inspection was conducted between June 22 and June 30, 2026. The company emphasized that none of the observations relate to data integrity and there are no repeat observations, describing them as procedural in nature. Glenmark stated it does not anticipate any impact on the supply of its commercial products.
As reported by CNBC TV18, Glenmark will work closely with the US FDA to address the observations and submit its response to the regulator within the stipulated timeline. A Form 483 is a list of observations made during the inspection and is issued by USFDA inspectors post completion. The company is given 15 days to submit its response explaining what steps will be taken to resolve the observations made by the USFDA. A Form 483 does not represent a final FDA determination regarding the facility's GMP compliance.
According to CNBC TV18, Glenmark Pharmaceuticals has projected FY27 revenue of ₹17,000-18,000 crore, with EBITDA margins expected to remain in the 21-22% range. Anurag Mantri, Executive Director & Global Chief Financial Officer, highlighted continued momentum in India, expansion in the US respiratory and injectable segments, and new product launches across Europe and emerging markets as key contributors to future growth. The company's long-term ambition is to become a global innovation-led pharmaceutical company, with branded products currently contributing about 60% of revenue and targeting a 70% share by 2030 through in-licensed therapies, specialty products and global brand expansion.
As reported by CNBC TV18, shares of Glenmark Pharmaceuticals Ltd ended at ₹2,204.90, down by ₹18.70, or 0.86%, on the BSE following the announcement. The stock movement reflects investor reaction to the regulatory inspection results and the company's financial projections for the upcoming fiscal year.
